Pharmacokinetic, pharmacodynamic, and safety profiles of PEGylated interferon beta-1a in healthy volunteers: Results from two Phase 1 clinical studies

被引：2

作者：

Davar, Gudarz ^{[1
]}

Richman, Sandra ^{[1
]}

Hitchman, Stacy ^{[1
]}

Glick, Gabrielle ^{[1
]}

Subramanyam, Meena ^{[1
]}

Hu, Xiao ^{[1
]}

Lerner, Michaela ^{[1
]}

Miller, Larisa ^{[1
]}

Nestorov, Ivan ^{[1
]}

Liu, Shifang ^{[1
]}

Zhu, Ying ^{[1
]}

Baker, Darren ^{[1
]}

Panzara, Michael A. ^{[1
]}

机构：

[1] Biogen Idec Inc, Cambridge, MA USA

来源：

CYTOKINE | 2009年 / 48卷 / 1-2期

关键词：

D O I：

10.1016/j.cyto.2009.07.084

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：21 / 21

页数：1

共 50 条

[1] Pharmacokinetic, pharmacodynamic, and safety profiles of PEGylated interferon beta-1a in healthy volunteers: results from two phase 1 clinical studies
Davar, G.
Richman, S.
Hitchman, S.
Glick, G.
Subramanyam, M.
Hu, X.
Lerner, M.
Miller, L.
Nestorov, I.
Liu, S.
Zhu, Y.
Panzara, M. A.
MULTIPLE SCLEROSIS, 2009, 15 (09): : S125 - S125
[2] Pharmacokinetic and Pharmacodynamic Profile of PEGylated Interferon Beta-1a in Healthy Volunteers: Results from Two Phase 1 Clinical Studies
Hu, Xiao
Subramanyam, Meena
Lerner, Michaela
Miller, Larisa
Nestorov, Ivan
Davar, Gudarz
NEUROLOGY, 2009, 72 (11) : A316 - A317
[3] Immunogenicity of PEGylated Interferon Beta-1a: Data from Preclinical and Phase 1 Clinical Studies
Baker, Darren
Lerner, Michaela
Subramanyam, Meena
Davar, Gudarz
Goelz, Susan
van Beers, Miranda
Schellekens, Huub
NEUROLOGY, 2010, 74 (09) : A544 - A545
[4] Phase 1 Studies of the Safety, Pharmacokinetics and Pharmacodynamics of Subcutaneous PEGylated Interferon-Beta in Healthy Volunteers
Grabstein, Kenneth
Nairn, Natalie
Wang, Andrea
Graddis, Tom
Jusko, William
Burge, Daniel
NEUROLOGY, 2012, 78
[5] The safety, tolerability and pharmacodynamic responses of interferon beta-1a (Rebif®) versus interferon beta-1b (Betaseron®) in healthy male volunteers.
Gariepy, S
Marier, J
Potvin, D
Di Marco, M
Byrnes, W
Abdul-Ahad, A
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P32 - P32
[6] Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone in Healthy Volunteers
Nakamura, Tadakatsu
Kawaguchi, Atsuhiro
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (04): : 353 - 365
[7] COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects
Hu, Xiao
Shang, Shulian
Nestorov, Ivan
Hasan, Jawad
Seddighzadeh, Ali
Dawson, Katherine
Sperling, Bjorn
Werneburg, Brian
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (02) : 380 - 388
[8] Pregabalin pharmacokinetics and safety in healthy volunteers: Results from two Phase 1 studies
Bockbrader, HN
Hunt, T
Strand, J
Posvar, E
Sedman, A
NEUROLOGY, 2000, 54 (07) : A421 - A421
[9] Pharmacokinetics, pharmacodynamics and tolerability of an innovative pegylated interferon beta-1a BCD-054 in healthy volunteers
Nikolskaia, M.
Filon, O.
Pashkevich, A.
Skripkin, A.
Chernovskaya, T.
Ivanov, R.
MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 685 - 686
[10] COMPARE: a phase 1 pharmacokinetic study of subcutaneous peginterferon beta-1a vs subcutaneous interferon beta-1a over 2 weeks in healthy subjects
Hu, X.
Shang, S.
Nestorov, I.
Dawson, K.
Sperling, B.
Werneburg, B.
MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 597 - 598

← 1 2 3 4 5 →